These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 17702770)
1. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Guillaume-Czitrom S; Berger C; Pajot C; Bodaghi B; Wechsler B; Kone-Paut I Rheumatology (Oxford); 2007 Oct; 46(10):1570-3. PubMed ID: 17702770 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581 [TBL] [Abstract][Full Text] [Related]
3. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304 [TBL] [Abstract][Full Text] [Related]
4. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease. Park JY; Chung YR; Lee K; Song JH; Lee ES Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420 [TBL] [Abstract][Full Text] [Related]
6. Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease. Diwo E; Gueudry J; Saadoun D; Weschler B; LeHoang P; Bodaghi B Ocul Immunol Inflamm; 2017 Feb; 25(1):76-84. PubMed ID: 27541620 [TBL] [Abstract][Full Text] [Related]
7. Results of interferon alpha-2a therapy in patients with Behcet's disease. Yalçindağ FN; Uzun A J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657 [TBL] [Abstract][Full Text] [Related]
8. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients]. Stübiger N; Kötter I; Deuter C; Zierhut M Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868 [TBL] [Abstract][Full Text] [Related]
9. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075 [TBL] [Abstract][Full Text] [Related]
10. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study. Kötter I; Eckstein AK; Stübiger N; Zierhut M Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053 [TBL] [Abstract][Full Text] [Related]
11. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a]. Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983 [TBL] [Abstract][Full Text] [Related]